Biologics & Advanced Molecules Science Days 2026 brought focused scientific exchange to Prague
Biologics & Advanced Molecules Science Days 2026 successfully brought together experts from biotech, pharma, regulatory, clinical, analytical, bioanalytical, and manufacturing environments for two days of focused scientific exchange in Prague.
Conscio Group and Paras Biopharmaceuticals Partner to Advance Romiplostim Biosimilar Toward European and US Registration
Development and registration partnership signed at Conscio Group’s Biologics and Advanced Molecules Day, in the presence of the Ambassador of Finland to the Czech Republic
Conscio Group Enters Italy with Acquisition of Studio F2 and Metralab
Conscio Group has entered the Italian market through the acquisition of Studio F2 and Metralab, two ACCREDIA-accredited food testing laboratories in Lombardia, strengthening its European food testing network.
How to Deal with the Matrix Effect as an Unavoidable Phenomenon: A Current Perspective
This white paper reviews the current status of the matrix effect ten years after the original publication. The answer is simple: this effect has a significant impact on quantitative results and must be carefully monitored and compensated for.
Nitrosamine Analogues in APIs and Drug Products: Risk, Testing Strategy, and Practical Pitfalls
Nitrosamine analogues are emerging as a new analytical and quality challenge across APIs and drug products. This expert-led article explores their origin, risk, and fit-for-purpose testing strategy.
ADC Performance by Design: From Linker Chemistry to DAR and Bioanalytical Insight
Registration is now open for our free expert-led webinar exploring the chemistry and bioanalytical strategies behind ADC performance.
Two High-Complexity Bioequivalence Studies: Transdermal Gel PK and Intragastric pH Monitoring
Bioequivalence projects are often perceived as “standardized by design.” In practice, however, the most demanding studies are those where execution is the true endpoint.
Bispecific Antibodies: A New Era in Therapeutic Innovation
Bispecific antibodies (bsAbs) are expanding the boundaries of modern therapeutics. By simultaneously engaging two different targets, these innovative molecules enable treatment strategies that can extend beyond the capabilities of traditional monoclonal antibodies.
Navigating the EMA Guideline on Equivalence of Topical Products: IVRT/IVPT Study Design
In April 2025, the long-awaited European Medicines Agency (EMA) Guideline on Quality and Equivalence of Locally Applied, Locally Acting Cutaneous Products came into effect.
Streamlined Evidence Strategies for Biosimilars: Analytics, PK and Immunogenicity in focus
Registration is now open for our free expert-led webinar on streamlined evidence strategies for biosimilar approval, with a special focus on analytics, PK design and immunogenicity.